Ghaswalla P, Joshi K, Hicks KA, Xiao Z, Fust K, Kohli M, Weinstein MC. Cost-effectiveness of Moderna's RSV vaccine, mRNA-1345 (mRESVIA) compared to no vaccination in adults 18-49 years at increased risk of severe RSV disease in the United States. Presented at the US Advisory Committee on Immunization Practices Respiratory Syncytial Virus Vaccines - Adults Work Group; May 2025. Atlanta, GA.